文献速递MDS 与骨髓增殖性肿瘤

纤维化前/早期原发性骨髓纤维化与WHO定义的原发性血小板增多症:次要临床诊断标准对疾病结局的影响

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
PubMed 文献 · Am J Hematol · 2017-06-09

该研究在170例纤维化前/早期原发性骨髓纤维化(pre-PMF)患者和225例原发性血小板增多症(ET)患者中评估了2016年修订版WHO诊断标准中四项次要临床标准(贫血、白细胞增多、乳酸脱氢酶升高、脾肿大)的相对频率。超过91%的pre-PMF病例至少满足其中一项标准,而ET患者仅48%满足。pre-PMF患者15年后进展为晚期/显性PMF的累积风险为36.9%。仅白细胞增多在pre-PMF和ET中均为总生存期的显著预测因素。分子特征显示pre-PMF中CALR突变较JAK2预后更佳,而ET中无此差异。

要点

  • 超过91%的pre-PMF病例至少满足一项次要临床诊断标准,而ET患者仅48%。
  • pre-PMF患者15年后进展为晚期/显性PMF的累积风险为36.9%。
  • 仅白细胞增多在pre-PMF和ET中均为总生存期的显著预测因素。

核心结论

  • pre-PMF与ET的不同结局及分子遗传学数据支持二者为两种不同实体,而非同一疾病的连续谱。
  • 尽管略低于50%的ET患者也显示一项或以上次要临床标准,但通过整合组织形态学诊断和次要临床标准的存在,可实现ET与pre-PMF的准确区分。

研究设计与样本

  • 研究纳入170例pre-PMF患者和225例ET患者,评估2016年修订版WHO诊断标准中四项次要临床标准的相对频率。

主要发现

  • 超过91%的pre-PMF病例显示一项或以上诊断所需的次要临床特征,而ET患者仅48%。
  • pre-PMF患者15年后进展为晚期/显性PMF的累积风险为36.9%。
  • 在pre-PMF和ET中,仅白细胞增多为总生存期的显著预测因素。
  • 分子特征显示pre-PMF中不同突变间生存期存在差异,CALR突变较JAK2预后更佳;ET中未见此差异。

关键数值与推荐

  • 2016年修订版WHO的pre-PMF诊断要求至少满足以下四项界值表达的次要临床标准之一:贫血、白细胞增多、乳酸脱氢酶升高和脾肿大。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydrogenase and splenomegaly. In this study, we evaluated the relative frequency of these four criteria in a group of 170 pre-PMF patients and compared them to 225 ET cases. More than 91% of pre-PMF cases showed one or more of these features required for diagnosis, by contrast with only 48% of ET patients. According to clinical data the cumulative risk of progression to advanced/overt PMF in pre-PMF was 36.9% after 15 years. After fitting cox regression models to analyze the impact of the minor criteria on overall survival, only leukocytosis remained as a significant predictor of survival in both pre-PMF and ET. Molecular characterization showed differences in survival in pre-PMF but not ET, with CALR being a more favorable mutation than JAK2. The different outcome of pre-PMF versus ET and associated molecular genetic data supports the concept of two different entities, rather than a continuum of the same disease. Although slightly less than 50% of ET patients also show one or more minor clinical criteria, accurate distinction between ET and pre-PMF is possible by following an integrated approach including histomorphological diagnosis and presence of minor clinical criteria.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jeryczynski G, Thiele J, Gisslinger B, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017. PMID: 28543356. doi:10.1002/ajh.24788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。